HHS eases enforcement on six peptides: what it is, and what it means in Canada
News from Oct 28, 2026. Updated October 29, 2026. Based on news reports, not the formal notice. News, not advice.
on Oct 28, 2026 the US Department of Health and Human Services (HHS) said it will temporarily allow compounding pharmacies to make six peptides available by prescription: BPC-157, TB-500, epitalon, MOTS-c, KPV and semax.
- HHS says the policy does not grant FDA approval or establish clinical safety and effectiveness.
- The reports I found do not mention Canada.
What was announced
| Question | What reports say |
|---|---|
| Who | HHS, on Oct 28, 2026 |
| Which peptides | BPC-157, TB-500, epitalon, MOTS-c, KPV, semax |
| What changes | Compounding pharmacies may make them on a temporary basis, by prescription |
| Conditions HHS listed | Patient-specific prescriptions, traceable ingredients, quality testing, safety reporting |
| What it is not | An approval. HHS says it does not establish clinical safety and effectiveness |
| How long | Not stated in the ABC report |
Background
- In July 2026 an independent FDA advisory panel voted to recommend these six peptides for the 503A bulks list, which covers ingredients compounding pharmacies can use for individual prescriptions, see the vote scorecard.
- In 2023 the FDA classified 19 peptides as unsafe to compound, see what the later change did not do.
Still unclear
- How long the temporary allowance lasts, and when FDA formally decides on the bulks list.
- One law firm summary, reported by a newsletter, said a Federal Register notice was scheduled for Oct 30 with a two-week comment period. That is one secondary source and I have not confirmed it.
- A pharmacy-safety group filed a citizen petition on Oct 16 asking FDA not to allow compounding of the recommended peptides, per the same newsletter.
- ABC reports that no published clinical trials show these six are effective in humans for any condition.
What it means in Canada
The reports I found are about US pharmacies and do not mention Canada. A US enforcement decision does not change Canadian rules. The Canadian position I can verify is Health Canada's April 2026 advisory: peptides are generally regulated as prescription drugs, and a research use only label does not make a product legal, see what the advisory says and Health Canada versus FDA.
How to read news like this: how to read peptide news. The earlier FDA shift is covered in the policy reversal explainer.
Ready to order?
Enter the code at checkout. If you copied it, just paste it in the Promo code box in the order summary, then press Apply. It does not apply by itself. Confirm the discount line before you pay.
Common questions
Which peptides did HHS cover on Oct 28, 2026?
BPC-157, TB-500, epitalon, MOTS-c, KPV and semax, per ABC News and a secondary newsletter.
Does this approve those peptides?
No. HHS says the policy does not grant FDA approval or establish clinical safety and effectiveness.
Does it change the rules in Canada?
No. The reports I found concern US pharmacies and do not mention Canada. Health Canada's April 2026 advisory is the Canadian rule I can verify.
Is the Federal Register notice published?
One secondary source said it was scheduled for Oct 30. I have not confirmed it.
Sources
- ABC News: Some wellness peptides will become widely available, HHS says (Oct 28, 2026)
- The Peptide Briefs: Top Ten for Oct 22 to Oct 29, 2026 (newsletter, secondary source)
- Health Canada: think twice before injecting peptides bought online
Summarised in my own words. Read the originals for the full detail.